RM Global BioAccess Fund | Activity

Milestone

Portfolio company Alveus Therapeutics was named to Fierce Biotech's 2026 Fierce 15.

Alveus Therapeutics

Alveus Therapeutics RM Global BioAccess Fund

fiercebiotech.comOCT 2026

OCT 2026

Milestone

Alveus Therapeutics started the Phase 2 PRESERVE trial of ALV-100 for chronic weight management.

Alveus Therapeutics

Alveus Therapeutics RM Global BioAccess Fund

biospace.comSEP 2026

SEP 2026

Milestone

ShiraTronics completed enrollment in the RELIEV-CM2 pivotal trial for chronic migraine.

Shiratronics

Shiratronics RM Global BioAccess Fund

prnewswire.comJUN 3, 2026

JUN 3, 2026

Exit

Portfolio company Odyssey Therapeutics went public in an IPO raising more than $300M.

Odyssey Therapeutics

Odyssey Therapeutics RM Global BioAccess Fund

endpoints.newsMAY 2026

MAY 2026

Milestone

Cartography Biosciences announced a strategic investment from Samsung Ventures.

Cartography Biosciences

Cartography BiosciencesRM Global BioAccess Fund

biospace.comMAY 2026

MAY 2026

Milestone

Cartography Biosciences dosed its first patient in a Phase 1 trial of CBI-1214 for colorectal cancer.

Cartography Biosciences

Cartography BiosciencesRM Global BioAccess Fund

businesswire.comFEB 24, 2026

FEB 24, 2026

Milestone

Alveus Therapeutics announced the final close of its oversubscribed Series A, bringing total financing to $197M.

Alveus Therapeutics

Alveus Therapeutics RM Global BioAccess Fund

globenewswire.comFEB 24, 2026

FEB 24, 2026

Milestone

Cartography Biosciences signed a pharma deal with Pfizer.

Cartography Biosciences

Cartography BiosciencesRM Global BioAccess Fund

endpoints.newsJAN 2026

JAN 2026

Milestone

Acesion Pharma initiated a Phase 2 trial of AP31969 for atrial fibrillation.

Acesion Pharma

Acesion Pharma RM Global BioAccess Fund

acesionpharma.comJAN 2026

JAN 2026

Milestone

Odyssey Therapeutics announced an oversubscribed $213M Series D financing.

Odyssey Therapeutics

Odyssey Therapeutics RM Global BioAccess Fund

odysseytx.comSEP 2025

SEP 2025

Milestone

Nuvig Therapeutics announced a $161M Series B and progression to Phase 2 development.

Nuvig Therapeutics

Nuvig Therapeutics RM Global BioAccess Fund

businesswire.comDEC 5, 2024

DEC 5, 2024

New Fund

RMG-KB BioAccess Fund launched with a first closing of $60M and a worldwide life sciences venture focus.

RMG-KB BioAccess Fund

RM Global BioAccess Fund

prnewswire.comSEP 7, 2021

SEP 7, 2021

RM Global BioAccess Fund Activity

Portfolio company Alveus Therapeutics was named to Fierce Biotech's 2026 Fierce 15.

Announced its investment in Altay Therapeutics' $37M Series A for an oral DUX4 inhibitor for FSHD.

Alveus Therapeutics started the Phase 2 PRESERVE trial of ALV-100 for chronic weight management.

ShiraTronics completed enrollment in the RELIEV-CM2 pivotal trial for chronic migraine.

Portfolio company Odyssey Therapeutics went public in an IPO raising more than $300M.

Cartography Biosciences announced a strategic investment from Samsung Ventures.

Cartography Biosciences dosed its first patient in a Phase 1 trial of CBI-1214 for colorectal cancer.

Alveus Therapeutics announced the final close of its oversubscribed Series A, bringing total financing to $197M.

Cartography Biosciences signed a pharma deal with Pfizer.

Acesion Pharma initiated a Phase 2 trial of AP31969 for atrial fibrillation.

Odyssey Therapeutics announced an oversubscribed $213M Series D financing.

Nuvig Therapeutics announced a $161M Series B and progression to Phase 2 development.

RMG-KB BioAccess Fund launched with a first closing of $60M and a worldwide life sciences venture focus.